Navigation Links
Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control
Date:3/2/2012

SAN DIEGO, March 2, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the filing of a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition. Arena expects the EMA will accept the filing later this month and confirm the filing is sufficiently complete to permit a substantive review.

(Photo:  http://photos.prnewswire.com/prnh/20120302/LA63311)

"With rates of obesity tripling in many European countries over the last thirty years, there is a substantial unmet need for new treatments to manage weight," said Jack Lief, Arena's President and Chief Executive Officer. "We look forward to working with the EMA and our Rapporteur and Co-rapporteur during this centralized review process and to the potential approval of lorcaserin in E.U. member countries."

About Lorcaserin
Lorcaserin is a new chemical entity that is believed to act as a selective serotonin 2C receptor agonist. The serotonin 2C receptor is expressed in the brain, including the hypothalamus, an area believed to be involved in the control of appetite and metabolism. Arena has patents that cover lorcaserin in the United States, major European countries and other jurisdictions that in most cases are capable of continuing into 2023 without taking into account any patent term extensions or other exclusivity Arena might obtain.

Arena resubmitted to the U.S. Food and Drug Administration (FDA) the lorcaserin New Drug Application (NDA) in December 2011, and the agency assigned a new Prescription
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 24, 2013 The potential of ... delivery of therapeutic agents has been receiving undeniable attention ... showing significant promise. The crucial formulation considerations for orally ... play a major role in the efficiency of pulmonary ... development of new formulation techniques and devices in recent ...
(Date:5/23/2013)... DIEGO , May 23, 2013 Neurocrine Biosciences, ... Kevin Gorman , President and Chief Executive Officer ... 38 th Annual dbAccess Health Care Conference in Boston.   ... May 30 at 11:20 a.m. Eastern Time / 8:20 a.m. ... accessed on the Company,s website at http://www.neurocrine.com . ...
(Date:5/23/2013)... , May 23, 2013  MGC Diagnostics Corporation ... global medical technology company, today scheduled a conference call ... of fiscal year 2013, ended April 30, 2013. The ... May 30, 2013. The Company will report financial results ... the markets close on Thursday, May 30, 2013. ...
Breaking Medicine Technology:Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2
... 22, 2011 Regeneron Pharmaceuticals, Inc. (NASDAQ: ... Food and Drug Administration (FDA) has accepted for review ... Injection for Subcutaneous Use for the prevention of gout ... Prescription Drug User Fee Act (PDUFA), the goal for ...
... Endoscopy, Inc.,s (OTCPK: SNDY) is pleased to announce that ... of $73,895.  Solos Endoscopy has consummated agreements which resulted ... Three Months period ending September 30, 2011.  The signed ... reduction of ongoing expenses by approximately $40,000 per quarter. ...
Cached Medicine Technology:Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 2Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 3Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 4Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 5Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 6Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 7Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 8Solos Endoscopy Finishes the 3rd Quarter With a Net Profit 2
(Date:5/25/2013)... Animals make great companions for senior citizens, but elderly people ... far more likely to crash than those who never drive ... included 2,000 licensed drivers aged 70 and older. The nearly ... drove with their pet in the car. Among those ... twice as high as among those who never drove with ...
(Date:5/25/2013)... Absolute Surgical Specialists, serving Sun City Center for ... throughout the country participating in Shop Local for a Cause. ... event as he understands what military families go through after ... said, “I wanted to give something back, as I not ... here too.” , Shop Local for a Cause has chosen ...
(Date:5/25/2013)... NY (PRWEB) May 25, 2013 On ... to brain cancer research and advocacy, comments on a ... Physics, that shows incorporating cold atmospheric plasma into brain ... , According to a Science Daily ... Physics (MPE), biologists and physicians demonstrated the “synergistic effect ...
(Date:5/25/2013)... Acuity Games ’ innovative brain games ... Word Hunt is available today, expanding it beyond ... Flash 2, Sudoku and Matchematics will roll out over the ... revolutionary lifetime brain fitness measurement have been re-optimized for the ... of brain fitness measurement in your pocket. What could ...
(Date:5/25/2013)... Ayurveda is the traditional medicine of India. ... a medical science, its scope enters into the realms of ... is that disease is the end result of living out ... health, one must discover where we are living out of ... back into perfect harmony. , The Foundations course in Mexico ...
Breaking Medicine News(10 mins):Health News:Seniors More Likely to Crash When Driving With Pet: Study 2Health News:Dr. Craig Amshel of Absolute Surgical Specialists Offering Bowel Prep During the Shop Local for a Cause Event 2Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2Health News:Acuity Games Apps Come to the iPhone 2Health News:Fundamentos de Ayurveda in Mexico (Ayurvedic Principles) Offered by Escuela de Ayurveda de California 2
... risk, data review finds , , TUESDAY, Dec. 2 (HealthDay News) ... safety of the drug Trasylol (aprotinin), used to limit bleeding ... of controversy in the United States, where it was removed ... Canadian and Australian researchers reviewed findings from 49 randomized clinical ...
... 2 Seniors, disabled,Michiganders, state HMOs and health insurance ... jam anti-consumer, anti-business legislation,through the lame duck session of ... "This could be a matter of life or death ... Policy Manager for the Michigan Disability Rights,Coalition. "A vote ...
... accounted for 3.5 percent of high school athletes, ... study to examine rare injuries and conditions of ... injuries, dental injuries, neck and cervical injuries and ... high morbidity, costly surgeries and treatments or life-altering ...
... advocates for teen,dating violence education from across the country ... -- Moms and Dads for Education to Stop Teen,Dating ... Lindsay Ann Burke,who was murdered by her abusive ex-boyfriend, ... on this national coalition that will,consist of parents, teachers ...
... the procedure, study says , , TUESDAY, Dec. 2 (HealthDay News) ... don,t respond to drugs would gain about five years of ... they had a certain form of brain surgery. , That,s ... modeling to assess the benefits of surgery of the temporal ...
... new brand name for the project formerly known as “Clinical Document Architecture ... the technical standards developed by the project and submitted to Health Level ... ... EON) December 2, 2008 -- "Our group has been working with ...
Cached Medicine News:Health News:Another Study Warns of Risk From Cardiac Surgery Drug 2Health News:Opposition Continues to Grow to Blues' Legislation 2Health News:Opposition Continues to Grow to Blues' Legislation 3Health News:Parents of Murdered Dating Violence Victim, Legislators, and Teachers Unite to Launch 'MADE' - Moms and Dads for Education to Stop Teen Dating Abuse 2Health News:Parents of Murdered Dating Violence Victim, Legislators, and Teachers Unite to Launch 'MADE' - Moms and Dads for Education to Stop Teen Dating Abuse 3Health News:Surgery a Boon for Most Common Form of Epilepsy 2Health News:Surgery a Boon for Most Common Form of Epilepsy 3Health News: "The Health Story Project" Adopted as New Brand by CDA4CDT : New Brand Underscores Comprehensive Electronic Health Records 2Health News: "The Health Story Project" Adopted as New Brand by CDA4CDT : New Brand Underscores Comprehensive Electronic Health Records 3Health News: "The Health Story Project" Adopted as New Brand by CDA4CDT : New Brand Underscores Comprehensive Electronic Health Records 4Health News: "The Health Story Project" Adopted as New Brand by CDA4CDT : New Brand Underscores Comprehensive Electronic Health Records 5
... products are offered as 1-piece or modular, ... modular instruments may be customized with handles ... ratchets, insulation and flush ports. Many standard ... specifications may affect delivery times. , ...
... Many special order products are offered as ... long lengths. The modular instruments may be ... options such as ratchets, insulation and flush ... Mediflex stock. Customer specifications may affect delivery ...
... products are offered as 1-piece or modular, ... modular instruments may be customized with handles ... ratchets, insulation and flush ports. Many standard ... specifications may affect delivery times. , ...
... products are offered as 1-piece or modular, ... modular instruments may be customized with handles ... ratchets, insulation and flush ports. Many standard ... specifications may affect delivery times. , ...
Medicine Products: